Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 661 to 670 of 1443 total matches.
Glycerol Phenylbutyrate (Ravicti) for Urea Cycle Disorders
The Medical Letter on Drugs and Therapeutics • Aug 18, 2014 (Issue 1449)
is about five times the cost per gram
of generic sodium phenylbutyrate.6
74
The Medical Letter ® Vol. 56 ...
The FDA has approved an oral liquid formulation of glycerol
phenylbutyrate (Ravicti – Hyperion) for chronic management
of patients ≥2 years old with urea cycle disorders that
cannot be adequately managed by a protein- restricted
diet. Sodium phenylbutyrate (Buphenyl, and generics),
another oral drug approved by the FDA for this indication,
has a bitter taste. The new product, which contains no sodium,
has little or no taste. Either drug must be used in
addition to a protein-restricted diet and, if needed, dietary
supplementation with amino acids and other nutrients.
Ceritinib (Zykadia) for Non-Small Cell Lung Cancer
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014 (Issue 1447)
of
ceritinib on progression-free and overall survival
remains to be determined.
63
The Medical Letter ® Vol ...
Ceritinib (Zykadia – Novartis), an oral tyrosine
kinase inhibitor, has received accelerated approval
from the FDA for treatment of patients with anaplastic
lymphoma kinase (ALK)-positive metastatic
non-small cell lung cancer (NSCLC) who have
progressed on or are intolerant to crizotinib (Xalkori).
It is the second tyrosine kinase inhibitor to be approved
for ALK-positive metastatic NSCLC; crizotinib was the
first. Translocations of the ALK gene are found in
about 5% of lung cancers; they occur predominantly
in nonsmokers with adenocarcinoma.
A Responsive Neurostimulator Device (RNS System) for Epilepsy
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014 (Issue 1447)
® Vol. 56 (1447) July 21, 2014
1. Drugs for epilepsy. Treat Guidel Med Lett 2013; 11:9.
2. JA French ...
The FDA has approved the use of a responsive
neurostimulator device (RNS System – NeuroPace)
for adjunctive treatment of adults with partial-onset
seizures that are not controlled with ≥2 antiepileptic
drugs and who have frequent and disabling seizures
and no more than 2 epileptogenic foci.
Oral Propranolol (Hemangeol) for Infantile Hemangioma
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014 (Issue 1447)
hemangioma.
60
The Medical Letter ® Vol. 56 (1447) July 21, 2014
DRUG INTERACTIONS — Patients receiving ...
The FDA has approved an oral solution of the
nonselective beta-adrenergic blocker propranolol
(Hemangeol – Pierre Fabre) for treatment of proliferating
infantile hemangiomas.
Extended-Release Oxycodone and Acetaminophen (Xartemis XR)
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014 (Issue 1447)
dosing interval (between 36 and 48 hours).2
60
The Medical Letter ® Vol. 56 (1447) July 21, 2014
tion ...
The FDA has approved a fixed-dose extended-release
formulation of oxycodone and acetaminophen
(Xartemis XR – Mallinckrodt) for oral treatment of
acute pain severe enough to require an opioid. Oxycodone
is available in the US as a single entity in oral
immediate-release (Oxecta, and others) and extendedrelease
(OxyContin) formulations. Immediate-release
oxycodone is also available in combination with aspirin
(Percodan, and others), acetaminophen (Percocet,
and others), or ibuprofen (see Table 1).
In Brief: Esomeprazole Strontium
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014 (Issue 1447)
® Vol. 56 (1447) July 21, 2014 Aciphex Dexilant Dexlansoprazole esomeprazole strontium GERD lansoprazole ...
The FDA has approved the proton pump inhibitor (PPI) esomeprazole strontium for use in adults for the same indications as esomeprazole magnesium (Nexium): treatment of gastroesophageal reflux disease (GERD), prevention of NSAID-induced gastric ulcers, eradication of Helicobacter pylori, and treatment of pathological hypersecretory conditions. It was first marketed in December 2013 as a branded drug (Esomeprazole Strontium) and a month later as a generic drug.Strontium is incorporated into bone. It is not recommended for use in children or during pregnancy because of the absence of safety data...
In Brief: Low-Dose Indomethacin (Tivorbex) for Pain
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014 (Issue 1447)
) for pain. Med Lett Drugs Ther
2014; 56:19.
60
The Medical Letter ® Vol. 56 (1447) July 21, 20 diclofenac ...
The same pharmaceutical company (Iroko) that recently marketed low-dose diclofenac (Zorvolex) for treatment of mild to moderate acute pain1 has now received approval from the FDA to market a low-dose oral formulation of indomethacin (Tivorbex) for the same indication. Tivorbex is available in 20- and 40-mg capsules; conventional immediate-release indomethacin capsules contain 25 mg and 50 mg of the drug.The rationale for this new product is the same as the one offered for Zorvolex: the drug is formulated as submicron particles that increase surface area, leading to faster dissolution and...
Drugs for HIV Infection
Treatment Guidelines from The Medical Letter • Feb 01, 2014 (Issue 138)
for HIV Infection
8 Treatment Guidelines from The Medical Letter • Vol. 12 (Issue 138) • February 2014 ...
Antiretroviral therapy is recommended for all HIV-infected
patients, both to reduce the risk of disease
progression and to prevent transmission of the virus to
others. Various guidelines for treatment of HIV infection
are available.
Drugs for Parasitic Infections
Treatment Guidelines from The Medical Letter • Aug 01, 2013 (Issue 143)
: 800-211-2769
Treatment Guidelines from The Medical Letter • Vol. 11 (Suppl) • 2013 e1
AMEBIASIS ...
With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians
anywhere may see infections caused by parasites. The table in this document lists first-choice and alternative drugs for most
parasitic infections.
Drugs for Bacterial Infections
Treatment Guidelines from The Medical Letter • Jul 01, 2013 (Issue 131)
from The Medical Letter • Vol. 11 (Issue 131) • July 2013
spp. is suspected, a combination of clindamycin ...
The text that follows reviews some common bacterial
infections and their empiric treatment pending the
results of culture and susceptibility testing. The recommendations
made here are based on the results of
susceptibility studies, clinical trials, and the opinions
of Medical Letter reviewers. Tables 1 and 2 list the usual
dosages of antibacterial drugs.